Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients

Annals of Oncology

Volumn 25, Issue 8, 2014, Pages 1536-1543

  Ali, H R ^a   Provenzano, E ^a   Dawson, S J ^a,b   Blows, F M ^b   Liu, B ^a,b   Shah, M ^a,b,c   Earl, H M ^a,b   Poole, C J ^d   Hiller, L ^d   Dunn, J A ^d   Bowden, S J ^e   Twelves, C ^f   Bartlett, J M S ^g,h   Mahmoud, S M A ^i,j   Rakha, E ^i,j   Ellis, I O ^i,j   Liu, S ⁱ   Gao, D ⁱ   Nielsen, T O ⁱ   Pharoah, P D P ^a,b,c   Caldas, Carlos ^a,b   more..

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b NIHR Cambridge Biomedical Research Centre   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF WARWICK   (United Kingdom)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^f UNIVERSITY OF LEEDS   (United Kingdom)

^g Edinburgh Cancer Research Centre   (United Kingdom)

^h NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

ⁱ UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^j BRITISH COLUMBIA CANCER AGENCY   (Canada)

more..

Author keywords

Breast cancer; Chemotherapy; Inflammation; Lymphocytes; Molecular subtypes

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; TRANSCRIPTION FACTOR FOXP3; ANTINEOPLASTIC AGENT; PROGESTERONE RECEPTOR; TUMOR MARKER; ANTHRACYCLINE;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; OBSERVATIONAL STUDY; PHASE 3 CLINICAL TRIAL (TOPIC); POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; STROMA; TRIPLE NEGATIVE BREAST CANCER; UNITED KINGDOM; AGED; BREAST NEOPLASMS; CLINICAL TRIAL; IMMUNOLOGY; LYMPHOCYTE COUNT; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL ANALYSIS; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR ASSOCIATED LEUKOCYTE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CELL INFILTRATION; DRUG EFFECT; HUMAN CELL; MAJOR CLINICAL STUDY; RISK REDUCTION; SURVIVAL TIME; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; LYMPHOCYTE COUNT; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RECEPTORS, PROGESTERONE; SURVIVAL ANALYSIS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84905186948     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu191     Document Type: Article

References (28)

1. Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960-1964.
2. Zhang L, Conejo-Garcia JR, Katsaros D et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348: 203-213.
3. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454.
4. Park S, Jiang Z, Mortenson ED et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010; 18: 160-170.
5. Liu S, Lachapelle J, Leung S et al. CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res 2012; 14: R48.
6. Mahmoud SM, Paish EC, Powe DG et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011; 29: 1949-1955.
7. Baker K, Lachapelle J, Zlobec I et al. Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade. Histopathology 2011; 58: 1107-1116.
8. Liu F, Lang R, Zhao J et al. CD8 cytotoxic T cell and FOXP3 regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res Treat 2011; 130: 645-655.
9. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999; 163: 5211-5218.
10. Mahmoud SM, Paish EC, Powe DG et al. An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer. Breast Cancer Res Treat 2011; 127: 99-108.
11. West NR, Kost SE, Martin SD et al. Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer. Br J Cancer 2013; 108: 155-162.
12. Denkert C, Loibl S, Noske A et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010; 28: 105-113.
13. Loi S, Sirtaine N, Piette F et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicinbased chemotherapy: BIG 02-98. J Clin Oncol 2013; 31: 860-867.
14. Ali HR, Dawson SJ, Blows FM et al. Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significance. Breast Cancer Res 2011; 13: R118.
15. Earl HM, Hiller L, Dunn JA et al. Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/ BR9601 trials. Br J Cancer 2012; 107: 1257-1267.
16. Blows F, Driver K, Schmidt M et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 2010; 7: e1000279.
17. McShane LM, Altman DG, Sauerbrei W et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005; 97: 1180-1184.
18. Nagalla S, Chou JW, Willingham MC et al. Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis. Genome Biol 2013; 14: R34.
19. Gruver AL, Hudson LL, Sempowski GD. Immunosenescence of ageing. J Pathol 2007; 211: 144-156.
20. Hoppin JA, Tolbert PE, Taylor JA et al. Potential for selection bias with tumor tissue retrieval in molecular epidemiology studies. Ann Epidemiol 2002; 12: 1-6.
21. Janssen KJ, Donders AR, Harrell FE, Jr et al. Missing covariate data in medical research: to impute is better than to ignore. J Clin Epidemiol 2010; 63: 721-727.
22. Ali AM, Dawson SJ, Blows FM et al. Comparison of methods for handling missing data on immunohistochemical markers in survival analysis of breast cancer. Br J Cancer 2011; 104: 693-699.
23. Berke G. The binding and lysis of target cells by cytotoxic lymphocytes: molecular and cellular aspects. Annu Rev Immunol 1994; 12: 735-773.
24. Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011; 8: 151-160.
25. Segal NH, Parsons DW, Peggs KS et al. Epitope landscape in breast and colorectal cancer. Cancer Res 2008; 68: 889-892.
26. Bates GJ, Fox SB, Han C et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006; 24: 5373-5380.
27. Ignatiadis M, Singhal SK, Desmedt C et al. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J Clin Oncol 2012; 30: 1996-2004.
28. Loi S, Michiels S, Salgado R et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol 2014; 25: 1544-1550.